Tax benefits help lift Pharmaniaga’s quarterly net profit to RM26.3 million
Nine-month earnings increased 72.1 per cent, while stronger concession demand helped revenue reach RM3.23 billion.
Tax benefits of RM16.4 million helped Pharmaniaga Bhd post a 261 per cent increase in third-quarter net profit. The group reported earnings of RM26.3 million for the quarter to 30 September 2026, against RM7.3 million a year earlier.
The quarterly dividend was set at 0.32 sen per share. Before zakat and taxation, profit totalled RM13 million, versus RM10.4 million previously. Operational efficiency efforts and RM3.2 million in interest savings from repaying some borrowings supported that result.
For January–September 2026, net earnings amounted to RM70.2 million, a gain of 72.1 per cent over the comparable RM40.8 million. Revenue reached RM3.23 billion, an 8.2 per cent rise from RM2.99 billion, driven mainly by higher concession-segment demand.
Nine-month profit measured before zakat and taxation was RM77.2 million, up 22 per cent against RM63.3 million. Interest savings totalled RM17.4 million after proceeds from the group’s regularisation plan were used to repay part of its borrowings.
Pharmaniaga plans to introduce nine pharmaceutical products during 2027, spanning vaccines, anti-infectives, oncology and cardiovascular treatments. It expects its Approved Product Purchase List concession to expand beyond 1,200 products during the concession period, from roughly 850.
The group is equipping four warehouses and aims to have them fully operational in the first quarter of 2027.
